We then divided the breast cancer patients into three subgroups based on the molecular subtypes: ER+/PR+/HER2- (hormone receptor-positive), ER+/PR+/HER2+ (hormone receptor and HER2-positive) and ER-/PR-/HER2- (triple-negative), and analyzed each subgroup for the Sec61α-associated patients' survival. This evidence concerns the gene NR4A1 and breast carcinoma.